DE2146674C3 - Faktor und seine Verwendung als Arzneimittel - Google Patents

Faktor und seine Verwendung als Arzneimittel

Info

Publication number
DE2146674C3
DE2146674C3 DE2146674A DE2146674A DE2146674C3 DE 2146674 C3 DE2146674 C3 DE 2146674C3 DE 2146674 A DE2146674 A DE 2146674A DE 2146674 A DE2146674 A DE 2146674A DE 2146674 C3 DE2146674 C3 DE 2146674C3
Authority
DE
Germany
Prior art keywords
factor
solution
atcc
centrifuged
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2146674A
Other languages
German (de)
English (en)
Other versions
DE2146674A1 (de
DE2146674B2 (de
Inventor
Nobuhiko Katunuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE2146674A1 publication Critical patent/DE2146674A1/de
Publication of DE2146674B2 publication Critical patent/DE2146674B2/de
Application granted granted Critical
Publication of DE2146674C3 publication Critical patent/DE2146674C3/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DE2146674A 1970-09-19 1971-09-17 Faktor und seine Verwendung als Arzneimittel Expired DE2146674C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP45081821A JPS5011478B1 (US20070167544A1-20070719-C00007.png) 1970-09-19 1970-09-19

Publications (3)

Publication Number Publication Date
DE2146674A1 DE2146674A1 (de) 1972-04-20
DE2146674B2 DE2146674B2 (de) 1980-11-27
DE2146674C3 true DE2146674C3 (de) 1981-10-29

Family

ID=13757137

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2146674A Expired DE2146674C3 (de) 1970-09-19 1971-09-17 Faktor und seine Verwendung als Arzneimittel

Country Status (4)

Country Link
JP (1) JPS5011478B1 (US20070167544A1-20070719-C00007.png)
DE (1) DE2146674C3 (US20070167544A1-20070719-C00007.png)
FR (1) FR2106626B1 (US20070167544A1-20070719-C00007.png)
GB (1) GB1309039A (US20070167544A1-20070719-C00007.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2253499B1 (US20070167544A1-20070719-C00007.png) * 1973-12-10 1977-11-04 Fabre Sa Pierre
JPS5432611A (en) * 1977-08-16 1979-03-10 Nobuhiko Katsunuma Glucocorticoid saving factor
JPS5594393A (en) * 1979-01-11 1980-07-17 Nobuhiko Katsunuma Gluco-corticoid sparing factor

Also Published As

Publication number Publication date
FR2106626B1 (US20070167544A1-20070719-C00007.png) 1975-08-01
FR2106626A1 (US20070167544A1-20070719-C00007.png) 1972-05-05
DE2146674A1 (de) 1972-04-20
DE2146674B2 (de) 1980-11-27
JPS5011478B1 (US20070167544A1-20070719-C00007.png) 1975-05-01
GB1309039A (en) 1973-03-07

Similar Documents

Publication Publication Date Title
EP0049847B1 (de) Alpha-Amylaseinaktivator, Verfahren zu seiner Herstellung, Mittel auf Basis dieses Inaktivators sowie dieser Inaktivator zur Regulierung des Blutzuckerspiegels
DE3109335C2 (de) Ebelacton A und B, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
DE2813353A1 (de) Substanz ks-2-a, verfahren zu deren herstellung und diese substanz enthaltendes mittel
DD215580A5 (de) Hypocholesterolaemisch aktives protein
DE2146674C3 (de) Faktor und seine Verwendung als Arzneimittel
DE1919837B2 (de) Leupeptine, deren Salze und Verfahren zu ihrer Herstellung
EP0057349B1 (de) Neues Peptid-Antibiotikum Komponente B, Verfahren zu seiner Herstellung sowie seine Verwendung in Arzneimitteln
DD222895A5 (de) Verfahren zur herstellung eines hypotriglyceridemisch aktiven polysaccharids
CH639133A5 (de) Verfahren zur herstellung einer antitumor wirksamen substanz mit immunostimulierender wirkung.
CH644896A5 (de) Polysaccharid, verfahren zur herstellung desselben und dasselbe enthaltendes, den cholesterinspiegel senkendes mittel.
DE2326916C2 (de) Anhydro-4-carbamoyl-5-hydroxy-1-ribofuranosylimidazoliumhydroxyd
DE2028403B2 (de) Pepstatin
EP0173950A2 (de) Neuer alpha-Glukosidase Inhibitor, Verfahren zur seiner Herstellung, seine Verwendung und pharmazeutische Präparate
EP0057812B1 (de) Neues Peptid-Antibiotikum Komponente A, Verfahren zu seiner Herstellung sowie seine Verwendung in Arzneimitteln
DE2950980C2 (de) Antibiotikum BN-183B und Arzneimittel, welche dieses enthalten
DE2803397A1 (de) Biologisch aktive substanz, verfahren zu deren herstellung und dieselbe enthaltendes mittel
DE2803681C2 (US20070167544A1-20070719-C00007.png)
DE1208449B (de) Verfahren zur Herstellung des Antibiotikums Ussamycin
DE2708493A1 (de) Neues antibiotikum am-1042
DE69214737T2 (de) Antibiotika NK374186A, NK374186B, NK374186B3 und NK374186C3, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2931792A1 (de) Antifibrotische substanz p-1894b, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
EP0173948A2 (de) Neue Pseudooligosaccharide mit alpha-Glukosidase-hemmender Wirkung, Verfahren zur deren Herstellung, deren Verwendung und pharmazeutische Präparate
DE3329255A1 (de) Neues verfahren zur herstellung einer substanz mit carcinostatischer und immunostimulierender aktivitaet
DE1795154C3 (de) Verfahren zur Herstellung eines neuen, Tuberactin genannten antibiotischen Wirkstoffes
CH657050A5 (de) Pharmazeutische zubereitung mit kontrollwirkung auf die phagozytfunktionen.

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee